Last reviewed · How we verify
Thymoglobulin
At a glance
| Generic name | Thymoglobulin |
|---|---|
| Also known as | ATG, Antithymocyte globulin, Anti-thymocyte globulin, rATG, Vidaza |
| Sponsor | Aaron Etra |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation (PHASE2, PHASE3)
- Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
- Uterine Transplantation and Pregnancy Induction in Women Affected by Absolute Uterine Infertility (NA)
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (PHASE1, PHASE2)
- Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders (PHASE2)
- Immune Tolerance Induction After Liver Transplantation (PHASE1, PHASE2)
- Allo HSCT for High Risk Hemoglobinopathies (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Thymoglobulin CI brief — competitive landscape report
- Thymoglobulin updates RSS · CI watch RSS
- Aaron Etra portfolio CI